Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company's pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:INNV
CUSIPN/A
Phone858-964-5123
Debt
Debt-to-Equity RatioN/A
Current Ratio0.72%
Quick Ratio0.39%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.82 million
Price / Sales3.06
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book14.00
Profitability
EPS (Most Recent Fiscal Year)($0.04)
Net Income$-6,500,000.00
Net Margins-73.78%
Return on Equity-299.94%
Return on Assets-62.83%
Miscellaneous
Employees12
Outstanding Shares192,550,000
